Docket No.

PG4709 In re Application of: BIGGADIKE, et. al. 10/066,964 NOV 1 0 2003 Application No. 02/04/2002 Filed: FORMULATION CONTAINING ANTI-INFLAMMATORY ANDROSTANE DERIVA For: 100.00 SmithKline Beecham Corporation interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term The owner, defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent g granted on pending second Application Number , filed on 10/066,836 February 04, 2002 The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney of record. 2. ☐ Small entity Large entity Owner/applicant is \$110.00 and is to be paid as follows: The terminal disclaimer fee under 37 CFR 1.20(d) is ☐ A check in the amount of the fee is enclosed. The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number _____ PTO suggested wording for terminal disclaimer was ☐ changed (if changed, an explanation should be supplied.) unchanged. 6 N. 2003 Dated: Tonature Name and Address of Person Signing

James P. Riek

Registration No.: 39,009 Telephone No.: 919-483-8022

Customer No.: 23347

I certify that this document and fee is being deposited on 11,04,03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Ban Younan

Typed or Printed Name of Person Mailing Correspondence

Docket No. PG4709

In re Applic	ation of: BIGO	GADIKE, et. al.		OIPE		
Application		66,964		()		
Filed:	02/04	/2002		(NOV 1 0 2003 🕏)		
For: FO	RMULATION CO	NTAINING ANTI-INFLA	MMATORY AN	IDROSTANE DERIVATIVES		
any patent defined in 3 granted on The owner	he instant applicat granted on the ins 5 U.S.C. 154 to 15 pending second A hereby agrees tha	stant application, which w 56 and 173 as shortened pplication Number at any patent so granted o	cept as provided tould extend bey by any terminal 10/067,020 on the instant appoint application a	of 100.00 percent below, the terminal part of the statutory term of rond the expiration date of the full statutory term disclaimer filed prior to the grant of any patent generation, filed on February 04, 2002 plication shall be enforceable only for and during are commonly owned. This agreement runs with see, its successors or assigns.		
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.						
Check eith	er box 1 or 2, if app	propriate.				
1.	For submissions agency, etc.), the	s on behalf of an orgar e undersigned is empowe	nization (e.g., c red to act on bel	orporation, partnership, university, government half of the organization.		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.						
2.	The undersigned	d is an attorney of record.				
3. Ow	ner/applicant is	· ☐ Small entity		ity		
The tern	ninal disclaimer fee	e under 37 CFR 1.20(d) is	\$110.0	and is to be paid as follows:		
☐ A ch	eck in the amount	of the fee is enclosed.				
oximes The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number $07-1392$						
PTO sugge	ested wording for to	erminal disclaimer was				
	☑ unchanged.	☐ changed (if change	ed, an explanatio	on should be supplied.)		
- Ja	30 Signati	ure	Dated:	La Nos Zer3		
James P. R	Name and Address of			I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mall under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
	n No.: 39,009			$\supset I$		
•	No.: 919-483-8022			- Bayfrural		
				Signature of Person Mailing Correspondence		
Customer 1	No.: 23347			Ban Younan Typed or Printed Name of Person Mailing Correspondence		

Docket No. PG4709

In re Applica	ation of:	BIGGADIK	E, et. al.					10	TPA	_
Application i	No.	10/066,964							پ ``	۱
Filed:		02/04/2002						ALCV MOV	1 0 2003	
For: FOI	RMULATIO	N CONTAIN	ING ANTI-INFLA	MM	ATORY AN	NDROSTAN	E DERIVATIV	VES 2	4	4
								M.	1	/
The owner,		Smi	thKline Beecham (Corp	oration		of	100.00	RADER	t
interest in the	ne instant ap	oplication her	eby disclaims, exc plication, which w	cept :	as provided extend hev	d below, the	terminal part	of the statut of the full sta	tory term o	ıt n
defined in 3	5 U.S.C. 15	4 to 156 and	173 as shortened	by a	ny terminal	disclaimer f	filed prior to the	e grant of an	ny patent g	•
granted on p	pending sec	ond Applications	on Number atent so granted o	n the	0/241,658	fil , Inlication sh	ed on Se	eptember 11,	2002	ċ
such period	that it and	anv patent gr	anted on the seco	nd a	pplication a	are commor	nly owned. Th	is agreemer	nt runs with	'n
any patent of	granted on t	ne instant app	olication and is bine	ding	upon grant	ee, its succ	essors or assig	gns.		
In making t	he above d	isclaimer, the	owner does not	discl	aim the ter	rminal part	of any patent	granted on	the instan	t
application	that would e	xtend to the	expiration date of t application, as sh	he fu	Ill statutory	term as def	fined in 35 U.S	.C. 154 to 19	56 and 173 atent grant	3 }
in the event	that any su	ch granted pa	atent: expires for t	failur	e to pav a	maintenanc	e fee. is held u	unenforceab	ile, is found	d
invalid by a	court of co	mpetent juris	diction, is statutor a reexamination c	rily d	lisclaimed i	in whole or	terminally disc	claimed und	ier 37 CFF	≺
expiration o	an claims c f its full stati	ancelled by a	shortened by any	term	inal disclair	ner filed pric	or to its grant.	terrimated	prior to the	_
•		, if appropriat								
_				· • •	/					
1.	For submi	ssions on be	ehalf of an organ signed is empowei	ızatı red t	on (e.g., c o act on bel	orporation, half of the o	paπnersnip, ι graanization.	university, g	jovernmen	τ
	• • •	•						U -4-4		_
information	and belief a	are believed :	s made herein of to be true; and fur	rther	that these	statements	were made w	/ith the kno\	wledge tha	It
willful false	statements	and the like	so made are puni	shat	ole by fine (or imprisoni	ment, or both,	under Secti	ion 1001 d)Ť
Title 18 of the patent issue	he United S ed thereon	tates Code a	nd that such willful	stat	ements ma	y jeopardize	e the validity o	i trie applica	ation or any	y
•		signed is an a	ttorney of record.				•			
						••				
			Small entity		Large enti	•				
The term	inal disclaim	er fee under	37 CFR 1.20(d) is		\$110.0	<u>)0 </u>	and is to be pai	id as follows	5 :	
☐ A che	eck in the ar	nount of the f	ee is enclosed.							
	Director is h	ereby authori	zed to charge any	fees	which may	be required	d, or credit any	overpayme	ent,	
to De	eposit Accou	int Number _	07-1392		- •					
PTO suggested wording for terminal disclaimer was										
☑ unchanged. ☐ changed (if changed, an explanation should be supplied.)										
1	ب ب				5.4.1		_			
7	or OC	Signature		_	Dated:	(e No.	1 2e03			_
				7		I certify that	t this document	and fee is bei	ng deposited	t
	Name and Ad	dress of Person S	igning	_l			l/ 06/53 wi in under 37 C.F.R	th the U.S. Pos . 1.8 and is ad		
James P. Ri	ek					Commissione 22313-1450.	er for Patents, P.C	D. Box 1450, A	lexandria, VA	4
Registration No.: 39,009							\sim 11	1		
Telephone No.: 919-483-8022							Jan 4	nunous	<u> </u>	
-						Sign	aure of Person M	illing Correspor	ndence	
							Ban Yo	nunan		
Customer N	o.: 23347					H	Dan 10	A Malling Co		

Typed or Printed Name of Person Mailing Correspondence

Docket No. PG4709


In re Application of					
Application No.					
Filed:					
For:	FORMUL				

BIGGADIKE, et. al.

10/066,964

02/04/2002

FORMULATION CONTAINING ANTI-INFLAMMATORY ANDROSTANE DERIVATI



The owner, SmithKline Beecham Corporation of 100.00 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent g granted on pending second Application Number 10/200,364 , filed on July 22, 2002

The owner hereby agrees that any patent so granted on the instant application hall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with

The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2, if appropriate.

1.	For submissions on behalf of an organization (e.g., corporation, partnership, university, governme	nt
	agency, etc.), the undersigned is empowered to act on behalf of the organization.	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Dated:

			•					
3.	Owner/applicant is		Small entity	\boxtimes	Large entity			
Th	ne terminal disclaimer fee	under	37 CFR 1.20(d) is		\$110.00	and is to be paid as follows:		
	☐ A check in the amount of the fee is enclosed.							
\boxtimes	The Director is hereby a to Deposit Account Num	uthori: nber _	zed to charge any 07-1392	fees	which may be	required, or credit any overpayment		
РТО	PTO suggested wording for terminal disclaimer was							

☑ unchanged. ☐ changed (if changed, an explanation should be supplied.)

Name and Address of Person Signing

ionature

The undersigned is an attorney of record.

James P. Riek

Registration No.: 39,009 Telephone No.: 919-483-8022 I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mall urder 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Ban Younan

Typed or Printed Name of Person Mailing Correspondence